DBVT — DBV Technologies S.A.

Is DBVT overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of October 3, 2026

DBV Technologies S.A. (DBVT) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $10.55. The rating moved from Neutral to Oversold on October 1, 2026.

See all oversold Healthcare stocks →

AI analysis

DBV Technologies S.A. is a small-cap, pipeline-centric biotech whose near-term value is driven by clinical and regulatory milestones. Market conditions have turned more risk-averse, reducing appetite for device/consumer-health offerings and increasing the cost of capital for companies that must fund development. Key strengths include focused therapeutic programs and upside from potential partnerships or positive trial data; primary vulnerabilities are cash burn, potential dilution, regulatory/reimbursement risk, and competitive pressure in specialty immunotherapies.

Key factors

  • Pipeline-driven valuation: company value tied to clinical progress and regulatory milestones rather than current commercial revenue.
  • Cash runway and financing need: small-cap biotech profile implies ongoing cash burn and a material likelihood of equity raises if near-term milestones are missed.
  • Regulatory and reimbursement uncertainty: success depends on favorable regulatory review and payer coverage in relevant markets.
  • Macro risk and investor risk-off: recent cautious market tone and cooling healthcare/device IPO window reduce appetite for speculative biotech/device names.
  • Competitive landscape: growing innovation in immunotherapies, biologics and specialty pharma may crowd markets DBV targets and pressure pricing/market share.
  • Partnership/licensing optionality: potential collaborations or M&A could be significant upside if clinical data or regulatory clarity emerges.

Risks

  • Clinical trial failure or weak efficacy/safety readouts leading to sharp downside in share price.
  • Regulatory setbacks or delays that push commercialization timelines and increase cash needs.
  • Dilution from equity raises at lower prices if cash runway is insufficient.
  • Adverse payer/reimbursement decisions or pricing pressure from Medicare negotiation dynamics.
  • Stronger-than-expected competition from alternative allergy/immunotherapy approaches or large-cap entrants.
  • Macro-driven liquidity contraction: continued market risk-off reducing capital access and secondary market support.

See today's live rating, score and targets

Members see the live hourly rating for DBVT — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.